Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Signs Three New Licenses For Cardiovascular Disease Gene

NEW YORK, Jan. 16-Variagenics said today that it has licensed its patents on the methylenetetrahydrofolate reductase gene to GeneOhm Sciences, Sciona, and Tm Bioscience. Variations in the MTHFR gene may be related to thromboembolic disease risk.


The licenses are worldwide and non-exclusive, and give each of the three companies the right to commercialize tests that identify polymorphisms in the gene.


Variagenics retains the right to develop tests relating to other diseases that involve the MTHFR gene.


Yesterday, the company announced a similar dealwith Celera Diagnostics.


GeneOhm, a California startup, is developing a chip-based technology to identify polymorphisms by interruptions in the flow of electrical current.


Sciona is a British diagnostics and pharmacogenomics firm.


Tm Bioscience, based in Toronto, is developing a battery of SNP diagnostic tests.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.